Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 12/2022

Open Access 01-12-2022 | Multiple Sclerosis | Review Article

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

Authors: Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, Barry Hendin, Timothy Vollmer

Published in: CNS Drugs | Issue 12/2022

Login to get access

Abstract

There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing–remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensus guidelines offering differing recommendations, there is broad heterogeneity in how the DMTs are used in clinical practice. Choosing a DMT for newly diagnosed patients with MS is currently a topic of significant debate in MS care. Historically, an escalation approach to DMT was used for newly diagnosed patients with RRMS. However, the evidence for clinical benefits of early treatment with high-efficacy therapies (HETs) in this population is emerging. In this review, we provide an overview of the DMT options and MS treatment strategies, and discuss the clinical benefits of HETs (including ofatumumab, ocrelizumab, natalizumab, alemtuzumab, and cladribine) in the early stages of MS, along with safety concerns associated with these DMTs. By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient.
Appendix
Available only for authorised users
Literature
1.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.PubMedCrossRef
2.
3.
4.
5.
6.
7.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.PubMedCrossRef
8.
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:789–800.PubMedCrossRef
9.
Marziniak M, Ghorab K, Kozubski W, Pfleger C, Sousa L, Vernon K, et al. Variations in multiple sclerosis practice within Europe - is it time for a new treatment guideline? Mult Scler Relat Disord. 2016;8:35–44.PubMedCrossRef
10.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46:907–11.PubMedCrossRef
11.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.PubMedPubMedCentralCrossRef
12.
13.
Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2020;77:58–64.PubMedCrossRef
14.
Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. 2015;2: e102.PubMedPubMedCentralCrossRef
15.
George IC, El Mendili MM, Inglese M, Azevedo CJ, Kantarci O, Lebrun C, et al. Cerebellar volume loss in radiologically isolated syndrome. Mult Scler. 2021;27:130–3.PubMedCrossRef
16.
Rojas JI, Patrucco L, Míguez J, Besada C, Cristiano E. Brain atrophy in radiologically isolated syndromes. J Neuroimaging. 2015;25:68–71.PubMedCrossRef
17.
De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868–76.PubMedCrossRef
18.
Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol. 2004;251:432–9.PubMedCrossRef
19.
Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, University of California San Francisco MS-EPIC Team, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85:653–66.PubMedPubMedCentralCrossRef
20.
Vollmer TL, Nair KV, Williams I, Alvarez E. Multiple sclerosis phenotypes as a continuum: the role of neurological reserve. Neurol Clin Pract. 2021;11:342–51.PubMedPubMedCentralCrossRef
21.
Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–9.PubMedCrossRef
22.
23.
Prosperini L, Capobianco M, Giannì C. Identifying responders and nonresponders to interferon therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2014;4:75–85.PubMedPubMedCentral
24.
Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, et al. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep. 2020;10:14244.PubMedPubMedCentralCrossRef
25.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, CLARITY Study Group, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.PubMedCrossRef
26.
Naismith RT. Multiple sclerosis therapeutic strategies: start safe and effective, reassess early, and escalate if necessary. Neurol Clin Pract. 2011;1:69–72.PubMedPubMedCentralCrossRef
27.
Bovis F, Carmisciano L, Signori A, Pardini M, Steinerman JR, Li T, et al. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. BMC Med. 2019;17:113.PubMedPubMedCentralCrossRef
28.
Smith AL, Cohen JA, Hua LH. Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurotherapeutics. 2017;14:952–60.PubMedPubMedCentralCrossRef
29.
Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31:233–43.PubMedCrossRef
30.
Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23:185–90.PubMedCrossRef
31.
Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, et al. Evaluation of a novel preference assessment tool for patients with multiple sclerosis. Int J MS Care. 2018;20:260–7.PubMedPubMedCentralCrossRef
32.
Davis BE, Lakin L, Binns CC, Currie KM, Rensel MR. Patient and provider insights into the impact of multiple sclerosis on mental health: a narrative review. Neurol Ther. 2021;10:99–119.PubMedPubMedCentralCrossRef
33.
Lakin L, Davis BE, Binns CC, Currie KM, Rensel MR. Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms—a narrative review. Neurol Ther. 2021;10:75–98.PubMedPubMedCentralCrossRef
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, ASCLEPIOS I and ASCLEPIOS II Trial Groups, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546–57.PubMedCrossRef
44.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab vs teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27:1289–90.
45.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, CARE-MS I investigators, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.PubMedCrossRef
46.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, CARE-MS II investigators, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.PubMedCrossRef
47.
Giovannoni G, Arnold DL, Bar-Or A, Havrdová E, Kappos L, Lublin F, et al. PO129 Neda analysis by epoch in the opera studies of ocrelizumab. J Neurol Neurosurg Psychiatry. 2017;88:A46.CrossRef
48.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, OPERA I and OPERA II Clinical Investigators, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34.PubMedCrossRef
49.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.PubMedCrossRef
50.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, AFFIRM Investigators, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.PubMedCrossRef
51.
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, AFFIRM Investigators, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–401.PubMedCrossRef
52.
Phillips JT, Giovannoni G, Lublin FD, O’Connor PW, Polman CH, Willoughby E, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011;17:970–9.PubMedCrossRef
53.
De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2018;24:222–6.PubMedCrossRef
54.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–37.PubMedCrossRef
55.
Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung H-P, oral cladribine for early MS (ORACLE MS) Study Group, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257–67.PubMedCrossRef
56.
Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21:693–703.PubMedCrossRef
57.
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, et al. Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurol Clin Pract. 2016;6:102–15.PubMedPubMedCentralCrossRef
58.
Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol. 2015;2:373–87.PubMedPubMedCentralCrossRef
59.
Signori A, Sacca F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, et al. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7:e878.PubMedPubMedCentralCrossRef
60.
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79:950–8.PubMedCrossRef
61.
Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320–7.PubMedPubMedCentralCrossRef
62.
Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, MSBase Study Group, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425–35.PubMedCrossRef
63.
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271–81.PubMedCrossRef
64.
Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536–41.PubMedPubMedCentralCrossRef
65.
Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658–65.PubMedCrossRef
66.
Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Christensen JR, Christensen MK, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95:e1041–51.PubMedCrossRef
67.
Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials. 2020;95:106009.PubMedCrossRef
68.
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5-48.PubMedCrossRef
69.
Emery P, Duquenne L. It’s never too soon to treat rheumatoid arthritis: finally, some supportive evidence. Lancet Rheumatol. 2020;2:e311–3.CrossRef
70.
71.
Prosperini L, Mancinelli CR, Solaro CM, Nociti V, Haggiag S, Cordioli C, et al. Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics. 2020;17:994–1004.PubMedPubMedCentralCrossRef
72.
AlSharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A narrative review. Neurol Ther. 2020;9:55–66.PubMedPubMedCentralCrossRef
73.
Fernández Ó. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75–83.PubMedCrossRef
74.
75.
76.
Yu H, Graham G, David OJ, Kahn JM, Savelieva M, Pigeolet E, et al. Population pharmacokinetic-B cell modeling for ofatumumab in patients with relapsing multiple sclerosis. CNS Drugs. 2022;36:283–300.PubMedPubMedCentralCrossRef
77.
Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95:e1854–67.PubMedPubMedCentralCrossRef
78.
Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134.PubMedPubMedCentralCrossRef
79.
Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Italian MS Register, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574.PubMedPubMedCentralCrossRef
80.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, MSBase study group, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16.PubMedCrossRef
81.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, MSBase Study Group, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–87.PubMedPubMedCentralCrossRef
82.
83.
Ziemssen T, Hoffmann F, Richter S, Engelmann U, White R. Alemtuzumab in a large real-life cohort: interim baseline data of the TREAT-MS study. Front Neurol. 2021;12: 620758.PubMedPubMedCentralCrossRef
84.
Ziemssen T, Engelmann U, Jahn S, Leptich A, Kern R, Hassoun L, et al. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS). BMC Neurol. 2016;16:109.PubMedPubMedCentralCrossRef
85.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler. 2022;28:1576–90.PubMedPubMedCentralCrossRef
86.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594–604.PubMedCrossRef
87.
Wolinsky JS, Arnold DL, Brochet B, Hartung H-P, Montalban X, Naismith RT, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19:998–1009.PubMedCrossRef
88.
Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63:395–400.PubMedCrossRef
89.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, HERMES Trial Group, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.PubMedCrossRef
90.
Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97:e1546–59.PubMedPubMedCentralCrossRef
91.
Wiendl H, de Seze J, Bar-Or A, Correale J, Cross AH, Kappos L, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in patients with relapsing multiple sclerosis over 3.5 years. Mult Scler. 2021;27:P931.
92.
Möhn N, Pfeuffer S, Ruck T, Gross CC, Skripuletz T, Klotz L, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm. 2020;7:654.PubMedCrossRef
93.
Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194:295–314.PubMedPubMedCentralCrossRef
94.
Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, et al. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Mult Scler Relat Disord. 2022;57:103431.PubMedCrossRef
95.
96.
97.
Häusler D, Häusser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, et al. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018;115:9773–8.PubMedPubMedCentralCrossRef
98.
99.
Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73:790–4.PubMedCrossRef
100.
Goncuoglu C, Tuncer A, Bayraktar-Ekincioglu A, Ayvacioglu Cagan C, Acar-Ozen P, Cakan M, et al. Factors associated with fingolimod rebound: a single center real-life experience. Mult Scler Relat Disord. 2021;56:103278.PubMedCrossRef
101.
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.PubMedPubMedCentralCrossRef
102.
Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, TYSEDMUS and OFSEP Group, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm. 2016;3:e297.PubMedPubMedCentralCrossRef
103.
Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martinez F, Cabrera-Maqueda JM, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord. 2020;44:102311.PubMedCrossRef
104.
Rowles WM, Hsu W-Y, McPolin K, Li A, Merrill S, Guo CY, et al. Transitioning from S1P receptor modulators to B cell-depleting therapies in multiple sclerosis: clinical, radiographic, and laboratory data. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1183.PubMedPubMedCentralCrossRef
105.
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.PubMedCrossRef
106.
Smith TE, Kister I. Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies. Curr Neurol Neurosci Rep. 2021;21:36.PubMedPubMedCentralCrossRef
107.
Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–33.PubMedCrossRef
108.
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93:e1452–62.PubMedPubMedCentral
109.
Ryerson LZ, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7: e672.CrossRef
110.
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger R, et al. Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: updated analysis of the TOUCH® Prescribing Program database (1988). Neurology. 2020;94:1988.
111.
Ryerson LZ, Foley J, Kister I, Cutter G, Metzger R, Goldberg JD, et al. Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) compared with every-4-week (Q4W) dosing: updated analysis of the TOUCH® Prescribing Program Database (4419). Neurology. 2021;96:4419.
112.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, NOVA study investigators, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21:608–19.PubMedCrossRef
113.
Toorop AA, van Lierop ZYG, Strijbis EEM, Teunissen CE, Petzold A, Wattjes MP, et al. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2021;8: e904.PubMedCrossRef
114.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184–91.PubMedCrossRef
115.
Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, et al. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol. 2021;78:736–40.PubMedCrossRef
116.
Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2019;25:1196–201.PubMedCrossRef
117.
118.
119.
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35:317–30.PubMedPubMedCentralCrossRef
120.
Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870–85.PubMedPubMedCentralCrossRef
121.
Cross A, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, et al. Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab: data from the ALITHIOS study and post-marketing surveillance. Presented at: 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 13–15 October 2021; Virtual.
122.
Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult Scler Relat Disord. 2021;51: 102929.PubMedPubMedCentralCrossRef
123.
Giovannoni G, Boster AL, Berkovich R, Selmaj KW, Chung L, Shiota D, et al. Cases of COVID-19 in alemtuzumab-treated patients with MS: pharmacovigilance report (2059). Neurology. 2021;96:4.
124.
125.
Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78:1510–4.PubMedCrossRef
126.
Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990–2001.PubMedPubMedCentralCrossRef
127.
Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021;78:1529–31.PubMedPubMedCentralCrossRef
128.
Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581.PubMedPubMedCentralCrossRef
129.
Oreja-Guevara C, Ramirez CI, Alba-Suarez E, Gomez-Estevez I, Bullón-Sanchez C, Castro-Hernandez M, et al. COVID-19 vaccination and humoral immune response in people with multiple sclerosis. Mult Scler. 2021;27:728.
130.
131.
132.
133.
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.PubMedPubMedCentralCrossRef
134.
Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572.PubMedCrossRef
135.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, CARE-MS II and CAMMS03409 Investigators, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117–26.PubMedPubMedCentralCrossRef
136.
Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, CARE-MS I and CAMMS03409 Investigators, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–16.PubMedPubMedCentralCrossRef
137.
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27:390–7.PubMedCrossRef
138.
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Tysabri Observational Program (TOP) Investigators, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91:660–8.PubMedCrossRef
139.
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit/risk following review of trial and post-marketing data. Mult Scler. 2022;28:842–6.PubMedCrossRef
140.
141.
Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, et al. Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf. 2020;43:635–43.PubMedPubMedCentralCrossRef
142.
Carnero Contentti E, Correale J. Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Exp Opin Emerg Drugs. 2020;25:377–81.CrossRef
143.
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, et al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight. 2018;3:124714.PubMedPubMedCentralCrossRef
144.
Pender M, Hodgkinson S, Broadley S, Lindsey J, Ioannides Z, Munson D, et al. Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with progressive forms of multiple sclerosis. Mult Scler. 2019;25:P1657.
145.
Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388:576–85.PubMedCrossRef
146.
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321:165–74.PubMedPubMedCentralCrossRef
147.
Ge F, Lin H, Li Z, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2019;40:479–87.PubMedCrossRef
148.
Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology. 2017;88:2115–22.PubMedCrossRef
149.
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:845–54.PubMedCrossRef
150.
Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R, National Medical Advisory Committee of the National Multiple Sclerosis Society. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021;78:241–6.PubMedCrossRef
151.
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and EBMT (JACIE), et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55:283–306.PubMedCrossRef
152.
Chung KK, Altmann D, Barkhof F, Miszkiel K, Brex PA, O’Riordan J, et al. A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann Neurol. 2020;87:63–74.PubMedCrossRef
Metadata
Title
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Authors
Léorah Freeman
Erin E. Longbrake
Patricia K. Coyle
Barry Hendin
Timothy Vollmer
Publication date
01-12-2022
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2022
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-022-00965-7

Other articles of this Issue 12/2022

CNS Drugs 12/2022 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Letter to the Editor

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”

Systematic Review

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis

Letter to the Editor

Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”

Original Research Article

Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects

Original Research Article

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients